Orbital and optic nerve complications of inflammatory bowel disease  by Katsanos, Andreas et al.
Ava i l ab l e on l i ne a t www.sc i enced i r ec t . com
ScienceDirect
Journal of Crohn's and Colitis (2013) 7, 683–693REVIEW ARTICLE
Orbital and optic nerve complications
of inflammatory bowel disease
Andreas Katsanos a, Ioannis Asproudis a,⁎, Konstantinos H. Katsanos b,
Anna I. Dastiridou c, Miltiadis Aspiotis a, Epameinondas V. Tsianos ba Ophthalmology Department, University of Ioannina, Ioannina, Greece
b 1st Department of Internal Medicine & Hepato-Gastroenterology, University of Ioannina, Ioannina, Greece
c University Ophthalmology Clinic of Larissa, Larissa, GreeceReceived 2 July 2012; received in revised form 11 September 2012; accepted 27 September 2012Abbreviations: CD, Crohn's disease
TNF, tumour necrosis factor; UC, ulcer
⁎ Corresponding author at: Ophthalm
2651 099 657.
E-mail address: asproudisi@yahoo.g
1873-9946/$ - see front matter © 2012
http://dx.doi.org/10.1016/j.crohns.20KEYWORDS
Inflammatory bowel
disease;
Optic neuritis;
Retrobulbar neuritis;
Orbital pseudotumor;
Orbital inflammatory
disease;
Anti-TNF
Abstract
Background and aims: Extraintestinal manifestations of inflammatory bowel disease (IBD) can
involve the orbit and the optic nerve. Although these manifestations are rare, they can be
particularly serious as they can lead to permanent loss of vision. The aim of the review is to
present the existing literature on IBD-related optic nerve and orbital complications.
Methods: A literature search identified the publications reporting on incidence, clinical
features and management of IBD patients with optic nerve and orbital manifestations.
Results: Posterior scleritis and orbital inflammatory disease (orbital pseudotumor) are the most
commonly encountered entities affecting the structures of the orbit. On the other hand, the
optic nerve of IBD patients can be affected by conditions such as optic (demyelinating) neuritis
(“retrobulbar” neuritis), or ischaemic optic neuropathy. Other neuro-ophthalmic manifestations
that can be encountered in patients with IBD are related to increased intracranial pressure or
toxicity secondary to anti tumour necrosis factor (anti-TNF) agents.
Conclusions: IBD-related optic nerve and orbital complications are rare but potentially
vision-threatening. Heightened awareness and close cooperation between gastroenterologists
and ophthalmologists are warranted.
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IBD remains a matter of controversy. Although earlier surveys
and chart review studies have estimated the prevalence of
ocular findings in IBD at 3.6–6.3%,1–5 a population-based study
has found ocular involvement in 1%–2% of IBD patients.6 On the
other hand, tertiary centre surveys indicate that ocular findings
in IBD patients may be significantly more prevalent when a
thorough evaluation by an ophthalmologist is performed.7 InFigure 1 Schematic diagram of thefact, in their survey, Yilmaz et al.8 found that 60% of their CD
patients had ocular findings.
This review presents the rare but potentially blinding
extraintestinal manifestations of IBD that involve the optic
nerve and the other elements located in the orbit, i.e.
extraocular muscles, lacrimal gland and posterior sclera
(Figs. 1 and 2). The rationale of including these particular
extraintestinal manifestations in the current article is
related both to the anatomical proximity of the involved
elements, and the frequently overlapping and confusing
clinical signs and symptoms produced by orbital conditions.anterior aspect of the right orbit.
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inflammatory bowel disease
2.1. Clinical spectrum
2.1.1. Orbital pseudotumor
One of the least frequent, yet potentially sight-threatening
ophthalmic manifestations of IBD is “orbital pseudotumor”.
This non-specific term is loosely used to describe the
enlargement of retrobulbar anatomical elements due to
inflammation. The resultant symptoms and signs often resem-
ble those of retrobulbar tumours. Other terms often used to
describe this clinical entity include “orbitopathy”, and “orbital
inflammatory disease” (OID). The condition can be idiopathic,
or occur in association with a number of systemic inflammatory
diseases.9–12
Orbital pseudotumor is a rare extraintestinal manifestation
of IBD and virtually all available evidence comes from sporadic
case reports. Consequently, its exact association with clinical
characteristics of the intestinal disease and patient demo-
graphics is uncertain. Lakatos et al.,13 in a 25-year follow-up
study of 873 patients with IBD found only one case of orbital
pseudotumor in a woman with severe ulcerative pancolitis.
Nonetheless, published case reports indicate that the condi-
tion is most commonly associated with CD, rather than UC and
the majority of patients are women (Table 1). Although the
pathogenesis of orbital inflammatory disease in patients with
IBD is unknown, it is generally thought that immune-mediated
processes are involved. For example, an immune-complex-
type hypersensitivity reaction to a colonic antigen has been
suggested. This view is supported by the observation that IBD
patients with colitis or ileocolitis are more likely to have
ocular inflammation than those with only small bowel
disease.14,15
In contrast to ocular manifestations of IBD such as uveitis,2
the existing literature suggests that orbital complications are
not associated with a distinct pattern of intestinal disease
activity, duration or phenotype.
The clinical manifestations may vary widely depending on
the structures affected by the combined effects of inflamma-
tion, orbital pressure elevation and direct compression.
Retro-orbital pain (often worse at night and/or with eyeFigure 2 Schematic diagram of themovements), diplopia, ophthalmoplegia, proptosis, eyelid
swelling, decreased vision, conjunctival chemosis and injec-
tion are all common findings.2.1.2. Orbital myositis
Orbital myositis is a common subtype of orbital pseudotumor
in which one or more of the extraocular muscles are
affected. The clinical presentation is typically characterized
by acute onset, severe pain inside, behind or around the
eye, pain on eye movement, occasional diplopia and
conjunctival chemosis. A prompt response to a therapeutic
trial of systemic steroids is typical, but recurrences are
common.2.1.3. Posterior scleritis
With the exception of exophthalmos, the remaining symp-
toms and signs accompanying orbital myositis are often
encountered in IBD patients with posterior scleritis. This
condition is a potentially serious, usually painful disease of
the sclera, which can seriously affect vision if not managed
appropriately. Depending on whether the anterior or the
posterior segment of the eye is affected, scleritis can
respectively be characterized as anterior or posterior.
Although most types of anterior scleritis do not normally
result in major complications if treated early, posterior
scleritis frequently results in visual loss. The worse prognosis
and more frequent complication occurrence in cases with
posterior scleritis is explained by the fact that the posterior
sclera is impossible to visualize and can only be assessed by
means of ultrasonography or indirectly through the effects
that scleritis can cause to the overlying choroid and retina
(e.g. choroidal folds, exudative retinal detachment, etc.).
Importantly, macular involvement due to the neighbouring
inflammation can seriously affect central vision.2.1.4. Dacryoadenitis
An exceptionally rare orbital manifestation in patients with
CD is inflammatory involvement of the lacrimal gland
(dacryoadenitis). Typical signs and symptoms include tender
swelling of the upper eyelids with discomfort and
lacrimation.16–18temporal aspect of the left orbit.
Table 1 Reported cases of orbital involvement in patients with inflammatory bowel disease (IBD) along with their clinical characteristics and treatment. (M: man, W: woman, CD:
Crohn's disease, UC: ulcerative colitis).
Age/sex Presentation IBD Preceding vs
following IBD
diagnosis
Treatment Comment Reference
38/W Unilateral painful eye, diplopia UC Following (12 years) Systemic steroids Similar episode in
contralateral eye
Jain and Gottlob21
32/M Unilateral proptosis UC Following (3 years) Systemic steroids Macarez et al.81
“Young”/W Unknown UC Unknown Unknown Severe pancolitis Lakatos et al.13
12/W Bilateral periorbital oedema, ptosis,
proptosis
CD Preceding
(8 months)
Prednisone 2 mg/kg/day Bilateral recurrences Durno et al.82
14/W Bilateral proptosis, conjunctival
injection, unilateral eye pain, headache,
diplopia
CD Preceding
(approximately
8 months)
Prednisone 60 mg/day, bowel recession Bilateral recurrences Young et al.83
15/W Bilateral proptosis, eye movement
restriction, eyelid oedema, photophobia,
bitemporal headache, eye pain on
movement, conjunctival injection
CD Preceding (1 month) Dexamethasone 16 mg/day
Prednisone 40 mg/day
Camfield et al.84
17/W Unilateral orbital pain, upper eyelid
oedema, diplopia, ptosis.
CD Preceding (Crohn's
disease diagnosed
during work-up for
orbital condition)
Prednisone 60 mg/day Weinstein et al.85
40/W Bilateral eye pain with movement,
diplopia, blurry vision and periorbital
oedema in right eye
CD Following
(approximately
20 years)
Prednisone 60 mg/day Possibly numerous
previous attacks
Ramalho and
Castillo14
38/W Bilateral eye pain with movement,
diplopia. Left eye: visual field loss and
visual acuity reduction
CD Following (6 years) Pulse methylprednisolone and oral steroids Left eye: optic nerve
compressed due to
extraocular muscle
enlargement
Cheng et al.86
23/W Unilateral periorbital pain, frontal
headache, diplopia, conjunctival
injection, chemosis
CD Following (8 years) Pulsed methylprednisolone (1 g/day for three
days), i.v. cyclophosphamide (15 mg/kg every
two weeks, six doses), oral prednisolone
15 mg/day for twelve weeks
Previous bilateral
attacks of posterior
scleritis
Culver et al.87
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Presentation IBD Preceding vs
following IBD
diagnosis
Treatment Comment Reference
32/W Bilateral ocular pain, periorbital swelling,
ptosis, diplopia
CD Preceding (2 years) Corticosteroids 1 mg/kg daily (sic),
cyclosporine (sic), adalimumab 40 mg every
other week
Orbital inflammation
uncontrolled with
combination of
steroids and
cyclosporine
Hernández-Garfella
et al.28
35/W Unilateral proptosis CD Preceding (1 year) Steroids (sic) Diagnosis of orbital
inflammation was
based on past MRI
Bourikas et al.88
20/M Unilateral eye pain with movement,
frontal headache, diplopia,
CD Following (8 years) Prednisone 60 mg/day Contralateral attack of
orbital inflammation
during tapering
Squires et al.89
44/M Unilateral periorbital pain and oedema,
proptosis, restriction of gaze
CD Following (several
years)
Prednisolone 100 mg/day Suppurative
granulomatous
myositis
Leibovitch et al.90
38/W Frontal headache, eyelid swelling,
conjunctival hyperaemia, diplopia,
exophthalmos
CD Following Prednisolone 20 mg b.i.d. Verbraeken et al.91
54/W Unilateral proptosis and discomfort,
diplopia
CD Following (21 years) Prednisone 60 mg/day Contralateral
recurrence one year
later
Smith92
48/W Unilateral proptosis, periorbital pain and
oedema, diplopia, chemosis,
CD Preceding (2 years) Prednisone 60 mg/day Uni- and contralateral
recurrences
Maalouf et al.18
34/W Unilateral periorbital swelling, proptosis,
and painful diplopia
CD Unknown Poor results with prednisone and
methotrexate. Acceptable control with
infliximab and methotrexate 15 mg/week
Garrity et al.25
27/W Unilateral myositis CD Preceding (2 years) Poor results with per os and retrobulbar
steroids, methotrexate and radiotherapy.
Good control with infliximab only
Garrity et al.25
55/W Unilateral periorbital pain and oedema,
diplopia, ptosis, exophthalmos.
CD Following Prednisolone 125 mg/day. Later infliximab
(maintenance with 5 mg/kg every 8 weeks)
Contralateral
recurrence
Pimentel et al.93
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The diagnostic work-up should aim primarily at differen-
tiating OID from infectious orbital cellulitis and thyroid
orbitopathy. Orbital cellulitis is a potentially life-
threatening condition frequently associated with trauma,
antecedent sinus disease or dental procedures, and is often
accompanied by the classic signs of periocular erythema,
oedema, localized warmth and tenderness. Fever and leuko-
cytosis are also typical, but all these features are uncommon
in noninfectious OID. Patients with infectious orbital cellulitis
are usually hospitalized and treated with high doses of i.v.
antibiotics in order to avert potentially serious complications
such as cavernous sinus thrombosis or intracranial extension of
the septic inflammation with resultant brain abscess or
meningitis.
Thyroid orbitopathy poses the most frequent differential
diagnostic challenge. Typically, this condition has a painless
and insidious onset, is often symmetrical, slowly progressive,
and sometimes accompanied by systemic manifestations of
Graves' disease. Upper eyelid retraction, reduction of the
blinking frequency and limitation of movement opposite to
the affected muscle are additional findings pointing towards
thyroid orbitopathy.
Magnetic resonance imaging (MRI) can be invaluable in the
assessment of orbital conditions. In thyroid orbitopathy,
tendinous insertions are typically unaffected and the inflam-
matory swelling of extraocular muscles is usually limited to
muscle bellies, which remain well defined. In orbital myopathy,
on the other hand, involvement of the tendons is usual and the
affected muscles tend to have irregular or blurred con-
tours.14,19,20 Another difference often observed is that thyroid
orbitopathy affects multiple muscles, whereas orbital myositis
induces inflammation to a single muscle.21 The most commonly
affected muscles are the superior recti and oblique muscles, as
well as the medial recti. In general, inflammatory infiltrates
exhibit low signal intensity on T1-weighted images, variable
intensity on T2-weighted images, and marked, diffuse, and
irregular gadolinium enhancement. The long-standing, scleros-
ing variant of orbital inflammatory disease, on the other hand,
usually shows decreased signal intensity on T2-weighted
images.14
Despite the fact that MRI is the most commonly used
modality for the assessment of orbital conditions, there may
still exist a role for orbital ultrasonography in selected
cases.19 Orbital ultrasonography is a fast and inexpensive
modality for the evaluation of extraocular muscle inser-
tions, the examination of the posterior aspect of the globe
for signs of scleritis, and the examination for the presence
of orbital vascular malformations and intra- or extraocular
tumours. Orbital tissue biopsy is rarely indicated unless the
clinical picture is uncharacteristic or the response to
treatment is minimal. In cases of suspected dacryoadenitis,
fine needle biopsy is very rarely indicated, since a prompt
response to a therapeutic trial with steroids, together with
ultrasound and MRI imaging can nearly always differentiate
dacryoadenitis from lacrimal gland teratomas and
neoplasms.
Other, much less frequent entities that need to be
considered in the differential diagnosis include tumour with
or without acute inflammation, lymphoma, carotid-cavernous
fistula, and infiltrative myopathies.16,20,22–242.3. Treatment
The management of patients with OID mainly consists of
steroid administration per os or intravenously. The typical
scheme involves prednisone at a dose of 1 mg/kg/day. In
most patients, the response is favourable with rapid control
of symptoms. The anti-TNFα agent infliximab has been
shown to be useful in case reports and short series of
patients with recalcitrant or relapsing orbital inflammation
and various systemic inflammatory diseases including Crohn's
disease.25–27 Hernández-Garfella et al.28 also reported
favourable results with adalimumab in a patient with Crohn's
disease and recurrent orbital myositis. The role of radio-
therapy remains a matter of debate, as chart review studies
have reported both favourable and less favourable results
in patients with difficult-to-control idiopathic orbital
inflammation.29–32 Rarely, long-standing refractory cases
may need to be managed surgically with orbital decompres-
sion. Because orbital inflammatory disease can pose a
significant danger to the optic nerve if severe and/or
long-standing, visual acuity and visual field testing should
not be neglected during follow-up.
3. Optic nerve complications in patients with
inflammatory bowel disease
Optic nerve involvement in patients with IBD can occur as a
result of any of the following causes:• Damage of the optic nerve tissue per se as a result of
inflammation and/or ischaemia
• Intracranial hypertension
• Secondary to anti-tumour necrosis factor (anti-TNF)
agents.3.1. Clinical spectrum
3.1.1. Damage due to inflammatory and/or ischaemic
insults
In the case of direct optic nerve involvement, the
clinical manifestations may be those of neuroretinitis,33
papillitis,34–37 optic (demyelinating) neuritis (also referred
to as “retrobulbar” neuritis),33 or ischaemic optic neuropa-
thy.38,39 The pathomechanism responsible for neuroretinitis,
papillitis and retrobulbar neuritis is related to direct involve-
ment of neural tissue by peripapillary or retrobulbar inflam-
mation.40 On the other hand, the pathomechanism of
ischaemic optic neuropathy is related to occlusion of the
vascular bed supplying the optic nerve secondary to inflam-
mation41 or hypercoagulability.41–44
The association of IBD and demyelinating conditions
such as multiple sclerosis (MS), optic neuritis, myelitis, or
Guillain–Barre has been suggested. Retrospective cohort
and chart review studies have suggested that the concur-
rence of IBD and demyelinating diseases is more frequent
than expected.45–47 As discussed later, the use of the
recently-introduced anti-TNFα agents might further increase
the risk of demyelinating events in patients with IBD.
The limited existing literature does not suggest any distinct
pattern of association between intestinal disease activity,
Figure 4 Fundus photograph from the right eye of a patient
with non-arteritic anterior ischaemic optic neuropathy. The
margins of the disc are indistinct, the neuroretinal tissue is
elevated and whitish due to oedema. Splinter-like peripapillary
haemorrhages are also seen.
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3.1.1.1. Neuroretinitis and papillitis. In both neuroretinitis
and papillitis, painless blurring of vision and variable decline of
visual acuity are usual symptoms. Relative afferent pupillary
defects and colour perception abnormalities are also frequent.
In patients with neuroretinitis, fundoscopy reveals inflamma-
tion of the optic nerve head with involvement of the retina.
Typical findings include optic disc swelling with hyperaemia,
retinal oedema with cotton-wool spots, vascular engorgement
at the involved segments, and vitreous haziness. Fundus
fluorescent angiography is useful as a confirmatory test.
Papillitis is associated with swelling of the optic nerve head
with signs of neuroretinal tissue inflammation, vascular
engorgement and optic disc or peripapillary haemorrhages.
3.1.1.2. Optic (demyelinating) neuritis. Optic neuritis can
also present with similar complaints of blurry and/or de-
creased vision over a period of few hours to several days, but is
often accompanied by retrobulbar pain, sometimes worsening
with eye movements and at nighttime. In contrast to
neuroretinitis and papillitis, funduscopic findings in
retrobulbar neuritis are typically absent. However, if previous
attacks have occurred, optic disc pallor can be seen (Fig. 3).
3.1.1.3. Ischaemic optic neuropathy. This entity usually
presents with sudden painless visual acuity decline, fre-
quently accompanied by an altitudinal visual field defect.
Depending on whether the vascular insult occurred at the
vicinity or relatively far from the optic disc, funduscopic
findings may vary. In the vast majority of cases, the vascular
supply of the anterior portion of the optic nerve is affected
and fundoscopy reveals optic disc swelling with tiny splinter
haemorrhages and indistinct optic disc margins (Fig. 4). The
altitudinal visual field defects of patients with ischaemicFigure 3 Fundus photograph of a patient's right eye showing
optic disc pallor and atrophy as a result of repeated episodes of
optic neuritis.optic neuropathy point towards a vascular insult in the
distribution of the posterior ciliary arteries affecting mainly
the anterior (prelaminar) portion of the optic nerve.38,48
It should be noted that neuro-ophthalmic manifestations in
IBD patients might sometimes present bilaterally. For exam-
ple, Heuer et al.38 described the case of a 24-year old man
with Crohn's disease and bilateral ischaemic optic neuropathy,
whereas Lee et al.37 described the case of a 37-year old
woman with Crohn's disease and bilateral retrobulbar neuritis.
Also, Barabino et al.49 described a case of bilateral presumed
demyelinating optic neuritis in an 11-year old boy with CD.
Recurrences of retrobulbar neuritis are not uncommon.
Often, however, the unequivocal documentation of previous
optic neuropathy attacks is lacking, but the patients may
report episodes of blurred vision sometimes accompanied by
retrobulbar pain. Such typical history, when accompanied by
optic disc pallor or frank atrophy and compatible visual field
defects, is strongly supportive of recurrent optic neuropathy
attacks. Alternate optic neuritis in the right and left eye has
also been described in a 50-year old man with UC over the
course of few years.50 Retrobulbar neuritis in IBD patients
can occur without signs of ocular inflammation such as
uveitis or retinitis. For example, in a short case series,
Sedwick et al.33 found that three of five IBD patients with
clinical findings consistent with retrobulbar neuritis had no
evidence of ocular inflammation at presentation. Moreover,
van de Scheur et al.51 described a patient with Crohn's
disease and bilateral retrobulbar neuritis without other
evidence of ocular inflammation.
3.1.2. Damage due to intracranial hypertension
Intracranial hypertension (IH) can also be the cause of optic
nerve involvement in patients with IBD. In addition to the
typical symptoms of headache, nausea, vomiting, tinnitus,
690 A. Katsanos et al.and neck or back pain, frequent ophthalmic complains may
include blurred or dimmed vision, visual field scotomas, and
short episodes of vision loss or flashing lights (photopsiae). Of
interest to gastroenterologists is the fact that steroid
treatment has been implicated in some case reports as a
factor that may cause idiopathic IH.52–54 Although the precise
mechanism of such an adverse effect is poorly understood, it
has been suggested that IH may not be directly linked to
steroid use per se, but may instead occur due to cerebral vein
and cerebral sinus thrombosis in patients with defective
coagulation mechanisms and hyperviscosity.55,56 Indeed,
short series and a cohort study showed that patients with IBD
have several abnormalities in their blood clotting system that
may predispose to vascular incidents.41–43,57 Corticosteroid
withdrawal has also been associated with IH in case reports of
few patients with UC and CD through an unknown mecha-
nism.58,59 Idiopathic IH has also been described in three
patients treated with mesalamine,60 sulfasalazine61 or
mesalazine.62 Headache is not an infrequent adverse effect
of these medications. Since headache is also a very common
symptom in patients with IH, the clinical implication is that
patients receiving the afore-mentioned medications and
complain of headache should be evaluated by an ophthalmol-
ogist so that the possibility of idiopathic IH is excluded.3.1.3. Damage resulting from anti-TNFα adverse events
Several cases of optic neuropathy have been linked to
anti-TNFα agents in patients treated for various inflamma-
tory diseases. Infliximab, and more recently adalimumab,
have been successfully used for the management of patients
with IBD. Infliximab in particular has been incriminated for
retrobulbar optic neuropathy in patients with rheumatoid
arthritis,63–67 UC68,69 and CD70–73 (Table 2). In general, signs
of optic neuropathy appear several months after the
initiation of anti-TNFα treatment.65 Typical symptoms and
signs include retrobulbar pain worsened by ocular move-
ment, visual acuity reduction, relative afferent pupillary
defect, colour perception abnormalities, and visual field
defects with central or ceco-central scotomas. Fundoscopy
is often normal, but MRI reveals optic nerve demyelination.
The concurrent presence of demyelinating lesions in the
central nervous system has been described and can raise theTable 2 Neuro-ophthalmic manifestations in infliximab-
treated patients with Crohn's disease (CD) or ulcerative
colitis (UC) (M: man, W: woman).
Age/sex Inflammatory
bowel disease
Neuro-ophthalmic
manifestation
Reference
44/M UC Optic neuritis Hejazi et al.68
51/W UC Optic neuritis Mumoli et al.69
50/W CD Optic neuritis Mejico70
54/W CD Optic neuritis Strong et al.71
32/M CD Optic neuritis Felekis et al.72
55/M CD Optic neuritis Ouakaa-Kchaou
et al.73
68/M CD Bilateral toxic
anterior optic
neuropathy
Chan and
Castellanos76possibility of multiple sclerosis: Bidagouren et al.66 have
reported the case of a 76 year old woman treated with
infliximab for rheumatoid arthritis who presented with
retrobulbar neuritis and demyelination brain plaques.
The clinical importance of isolated retrobulbar optic
neuropathy in patients treated with anti-TNFα agents is related
to the fact that some of these patientsmay eventuallymanifest
multiple sclerosis.74 It remains unknown, however, if anti-
TNFα-induced optic nerve demyelination carries the same
prognostic relevance with regard to future manifestation of
MS, or it merely represents an isolated event. In other words, it
remains to be determined if anti-TNFα agents can de novo lead
to demyelinating diseases such as MS or retrobulbar neuritis, or
if they merely unmask a patient's existing predisposition for
such diseases. In any event, it seems prudent to consult and
closely monitor anti-TNFα-treated patients for the occurrence
of ophthalmic or neurological symptoms and signs. In such an
event, discontinuation of the anti-TNFα agent and commence-
ment of steroid treatment are mandatory.
Besides demyelinating retrobulbar neuritis, rare cases of
toxic anterior optic neuropathy have also been described in
infliximab-treated patients. ten Tusscher et al.75 were the
first to describe three cases of bilateral anterior toxic
neuropathy in middle-aged patients with rheumatoid arthri-
tis following their third infliximab infusion. Chan and
Castellanos76 also described a case of bilateral toxic anterior
optic neuropathy in a 68-year old man with Crohn's
oesophagitis who developed acute symptoms during his
third infliximab infusion. In all reports, the patients'
clinical picture was characterized by bilaterally decreased
vision with mostly central or inferior visual field defects.
Fundoscopy revealed swollen optic discs with capillary
dilation and leakage at fluorescent angiography. In contrast
to cases with retrobulbar neuropathy, MRI of the optic
nerves was normal, since demyelination was not the
pathomechanism behind these attacks. To exclude the
possibility of optic neuropathy secondary to giant cell
arteritis, corticosteroids were administered in all cases but
the response was invariably poor and recovery was not
observed. The peculiar occurrence of all incidents during, or
shortly after the third infliximab infusion might suggest that
the toxicity of this medication is dose- or time-dependent.
Adalimumab has also been associated with demyelinating
optic neuropathy in patients with various inflammatory condi-
tions. So far, however, no such events have been published in
adalimumab-treated patients with IBD. Chung et al.77 were the
first to describe two cases of unilateral retrobulbar neuritis in a
40-year old man with rheumatoid arthritis and a 55-year old
man with psoriatic arthritis. Of note, Li et al.78 and Kim and
Saffra79 have reported cases of patients with recalcitrant
ophthalmic inflammation who were treated with adalimumab
and developed both retrobulbar neuritis and multiple sclerosis.
Similarly, Bensouda-Grimaldi et al.74 described the case of a
32-year old woman with rheumatoid arthritis who had been
treated with adalimumab for two years and developed
retrobulbar optic neuritis as a first manifestation of MS.3.2. Investigations and diagnosis
In general, the diagnoses of neuroretinitis, papillitis, optic
neuritis and ischaemic optic neuropathy are based on the
691IBD-related orbital & optic nerve complicationscharacteristic ophthalmic findings already mentioned. Visual
acuity, visual field testing, fundoscopy and fundus fluorescent
angiography are necessary both for the diagnosis and
follow-up. It is important, however, to ensure that no other
underlying systemic or ophthalmic infectious or autoimmune
condition is responsible for the patient's condition. In cases of
suspected retrobulbar optic neuritis, MRI of the orbits, brain
and possibly the spinal cord is necessary in order to confirm or
refute areas of demyelination. It should also be stressed that
ischaemic optic neuropathy in relatively young patients may
be a manifestation of systemic hypertension, embolic disease,
connective tissue disorders, systemic arteritides or migraine.
Therefore, such conditions should be excluded before a
patient's ischaemic optic neuropathy can be attributed to IBD.
In patients suspected of having optic nerve involvement
related to IH, brain MRI and cerebrospinal fluid pressure
measurement might be necessary diagnostic procedures.
In IBD patients treated with anti-TNFα agents, it is
important to discriminate between the demyelinating and
the toxic type of optic neuropathy. Based on characteristic
symptoms and signs already described, the ophthalmic clinical
examination can often distinguish between the two entities,
but MRI is valuable in documenting or excluding demyelination
of the optic nerve.
3.3. Treatment
Unfortunately, no specific therapy has been found useful for
patients with neuroretinitis, papillitis and ischaemic optic
neuropathy and the prognosis is highly variable. Regarding
patients with optic neuropathy, the recommended treatment
typically consists of pulse methylprednisolone 1000 mg/day
for three days followed by oral prednisolone 1 mg/kg/day
tapered over few weeks. The prognosis for visual recovery is
typically very good.
In cases of optic nerve involvement secondary to IH, the
reduction of cerebrospinal fluid pressure with oral acetazol-
amide or, in refractory cases, with a shunt procedure is
necessary. The prognosis on the visual function depends on
how promptly and efficiently the intracranial pressure is
controlled. Because of variations in the duration of IH, the
level of the intracranial pressure and the individual patient's
optic nerve susceptibility to damage, frequent visual field
examination is necessary during the follow-up period so that
the effectiveness of therapy is judged.
Similar to idiopathic or MS-related optic neuritis, the usual
treatment of optic neuritis related to either IBD or the use of
anti-TNF agents consists of pulse methylprednisolone
1000 mg/day for three days followed by oral prednisolone
1 mg/kg/day tapered over few weeks. The prognosis is very
good with complete recovery being the rule.80 Unfortunately,
no specific therapy can be offered for the more rare toxic
variety of optic neuropathy described with anti-TNFα agents
and the response to steroids is very poor.
4. Conclusions
This review could not identify a sufficient number of
methodologically rigorous, high quality studies describing the
clinical characteristics and epidemiology of extraintestinal
complications involving the optic nerve and the otherstructures of the orbit in patients with IBD. This scarceness
of information most probably reflects the rarity of these
events. However, the possibility that such complications may
sometimes remain unrecognized cannot be dismissed. Despite
the fact that most of the available information comes from
case reports, the existing body of knowledge offers an
important, albeit fragmented, insight into the clinical fea-
tures and the treatment strategies for these complications.
In IBD patients, extraintestinal complications involving
the optic nerve and the other structures of the orbit are rare
but potentially serious, as they may lead to permanent loss
of vision. Close cooperation between ophthalmologists and
gastroenterologists is necessary for the successful manage-
ment of these patients.
4.1. Methods of literature search
TheMEDLINE databasewas used for the literature search of this
review. Articles irrespective of the year of publication were
used if deemed appropriate. The search included the following
keywords and their combinations with appropriate Boolean
operators: anti-TNF, Crohn's, demyelinating neuritis, inflam-
matory bowel disease, optic nerve, optic neuritis, orbit, orbital
inflammatory disease, orbital pseudotumor, orbitopathy,
retrobulbar neuritis and ulcerative colitis. After retrieving
pertinent articles using these keywords, a search was
conducted through the literature cited in these articles and
additional papers were identified. Papers in languages other
than English were also surveyed. Medical Subject Headings
(MeSH) searches were also conducted. The latest literature
search was performed in August 22nd 2012.
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